EXEL - Why Exelixis Stock Is Trading Lower Today | Benzinga
Exelixis, Inc. (NASDAQ: EXEL) shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in advanced neuroendocrine tumors.
What To Know: Exelixis announced the results on Sunday, highlighting that Cabozantinib lowered the risk of disease progression or death in patients with pancreatic NET and in patients with extra-pancreatic NET, compared to the placebo.
"Although progress has been made in recent years, there remains a critical need for new and effective therapies for patients with advanced neuroendocrine tumors. ...